首页> 外文期刊>Intensive care medicine >Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block?
【24h】

Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block?

机译:重症急性胰腺炎的微循环障碍治疗:我们应该阻断哪些介质?

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To compare the effect of different vasoactive mediator antagonists in the same model of severe acute pancreatitis (AP) and to evaluate whether combinations of the agents exhibit synergistic effects. DESIGN: Prospective experimental study. SETTING: Microcirculation and pancreas research laboratory at an university hospital. PARTICIPANTS: Hundred eighty anesthetized male Sprague-Dawley rats. INTERVENTIONS: Six hours after inducing AP by intra-ductal bile salt infusion and i.v. cerulein in 168 rats, these were randomized for therapy with (1) saline, (2) endothelin receptor antagonist (ET-RA), (3) platelet activating factor receptor antagonist (PAF-RA), (4) intercellular adhesion molecule-1 antibody (ICAM-1-AB) or different combinations (5-7). After 24 h the animals underwent a second laparotomy for intra-vital microscopic determination of pancreatic and colonic capillary permeability, blood flow and leukocyte-endothelial interaction. RESULTS: AP induction decreased capillary blood flow and increased permeability and leukocyte rolling. ET-RA, PAF-RA and ICAM-1-AB decreased capillary permeability, increased blood flow and reduced leukocyte rolling. ET-RA was most effective in decreasing capillary permeability in both organs as well as in increasing pancreatic capillary blood flow. Combining vasoactive mediator blockers did not further improve target parameters. CONCLUSIONS: This study supports previous observations that ET-RA, PAF-RA and ICAM-1-AB improve microcirculation in AP and that ET-RA is more effective than PAF-RA or ICAM-1-AB, especially in counteracting capillary leakage. Although this may suggest that they act through different mechanisms, antagonist combinations failed to improve microcirculation further. We conclude that ET-RA is the most promising candidate for a clinical trial to reduce capillary leakage in patients with AP.
机译:目的:比较不同血管活性介质拮抗剂在同一模型的严重急性胰腺炎(AP)中的作用,并评估这些药物的组合是否表现出协同作用。设计:前瞻性实验研究。地点:大学医院的微循环和胰腺研究实验室。参与者:一百八十只麻醉的雄性Sprague-Dawley大鼠。干预:通过导管内胆汁盐输注和静脉内注射诱导AP后六小时168只大鼠中的cerulein,将这些随机分配至(1)盐水,(2)内皮素受体拮抗剂(ET-RA),(3)血小板活化因子受体拮抗剂(PAF-RA),(4)细胞间黏附分子-1抗体(ICAM-1-AB)或其他组合(5-7)。 24小时后,对动物进行第二次剖腹术,以体内显微镜检查胰腺和结肠的毛细血管通透性,血流量和白细胞-内皮相互作用。结果:AP诱导减少毛细血管血流量,增加通透性和白细胞滚动。 ET-RA,PAF-RA和ICAM-1-AB降低毛细血管通透性,增加血流量并减少白细胞滚动。 ET-RA在降低两个器官的毛细血管通透性以及增加胰腺毛细血管血流方面最有效。合并血管活性介质阻滞剂不能进一步改善靶参数。结论:这项研究支持以前的观察,即ET-RA,PAF-RA和ICAM-1-AB改善了AP的微循环,并且ET-RA比PAF-RA或ICAM-1-AB更有效,特别是在抵抗毛细血管渗漏方面。尽管这可能表明它们通过不同的机制起作用,但拮抗剂的组合未能进一步改善微循环。我们得出的结论是,ET-RA是减少AP患者毛细血管渗漏的临床试验中最有希望的候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号